Acuitas Investments LLC Acquires 85,982 Shares of NextCure, Inc. (NASDAQ:NXTC)

Acuitas Investments LLC lifted its stake in NextCure, Inc. (NASDAQ:NXTC) by 30.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 372,799 shares of the company’s stock after acquiring an additional 85,982 shares during the period. Acuitas Investments LLC’s holdings in NextCure were worth $425,000 at the end of the most recent quarter.

NextCure Stock Performance

NXTC stock traded up $0.08 during trading on Friday, reaching $1.37. The company had a trading volume of 31,865 shares, compared to its average volume of 230,945. The company has a market cap of $38.22 million, a price-to-earnings ratio of -0.57 and a beta of 0.40. NextCure, Inc. has a twelve month low of $0.98 and a twelve month high of $2.57. The firm has a 50-day simple moving average of $1.74 and a 200-day simple moving average of $1.39.

NextCure (NASDAQ:NXTC) last released its earnings results on Thursday, March 21st. The company reported ($0.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.02. Sell-side analysts expect that NextCure, Inc. will post -1.65 earnings per share for the current year.

Analysts Set New Price Targets

NXTC has been the subject of several recent analyst reports. HC Wainwright boosted their price objective on shares of NextCure from $5.00 to $8.00 and gave the stock a “buy” rating in a research note on Friday, March 22nd. Needham & Company LLC restated a “buy” rating and set a $4.00 target price on shares of NextCure in a research note on Wednesday, March 20th.

About NextCure

NextCure, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells.